GlassScriptPhysician profile
Octavio Ramilo
NPI 1710947395
$413,234.07
in general payments reported to CMS, 2019-2025
10 companies · $206K in 2025
The $206K reported for 2025 was more than what 99% of Pediatric Infectious Diseases providers received nationally (typical 2025 total: $125).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $15K · 2021: $22K · 2022: $36K · 2023: $46K · 2024: $75K · 2025: $206K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $122K · Travel and Lodging: $115K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $88K · Food and Beverage: $2,010.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $121,709.79 |
| Travel and Lodging | $115,467.72 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $87,919.16 |
| Food and Beverage | $2,010.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $198,145.23 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $106,688.81 | 2019-2025 | Enflonsia, Gardasil 9 |
| Sanofi Pasteur INC. | $68,571.95 | 2019-2023 | |
| Modernatx, INC. | $21,817.16 | 2025 | |
| Pfizer International LLC | $7,261.00 | 2020-2021 | |
| Astrazeneca Uk Limited | $6,000.00 | 2022 | |
| Pfizer Chile S.A. | $2,049.92 | 2024 | |
| Eli Lilly and Company | $1,575.00 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $1,125.00 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Octavio Ramilo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.